Rifaquizinone is under clinical development by TenNor Therapeutics and currently in Phase I for Irritable Bowel Syndrome. According to GlobalData, Phase I drugs for Irritable Bowel Syndrome have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rifaquizinone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rifaquizinone overview
Rifaquizinone is under development for the treatment of acute bacterial skin and skin structure infection, prosthetic joint infections, biofilm-associated bacterial infections, hepatic encephalopathy, irritable bowel syndrome with diarrhea and gastrointestinal tract infections including superbug and diabetic foot infections. The drug candidate is administered through oral and intravenous routes. It is a rifamycin-quinolone based hybrid antibiotic. The drug candidate is a small molecule which acts by targeting RNA polymerase, DNA gyrase and DNA topoisomerase IV.
The drug candidate was also under development for the treatment of hyperammonemia, bacterial infections, helicobacter pylori infections and cirrhosis.
TenNor Therapeutics overview
TenNor Therapeutics is a biopharmaceutical company that develops novel drugs for the treatment of infectious diseases. The company’s pipeline product portfolio includes TNP-2198 oral, TNP-2092 injection, TNP-2092 oral, TNP-2092 external preparation and others. It also carries out research and development activities for developing new drugs. The company’s TNP-2198oral uses in helicobacter pylori infection, bacterial vaginosis and clostridium infection.. TenNor Therapeutics has collaborations with 3D Bio Optima, Colorado State University, JMI Laboratories, Peking University and others. The company operates in China. TenNor Therapeutics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Rifaquizinone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
